Trial intelligence / Profile preview

Vortioxetine for Major Depressive Disorder in India

NCT04288895Phase 4Completed

Sponsor
Lundbeck
Start
Feb 2020
Primary completion
Feb 2022
Modality
Small Molecules
Countries
1
01

Overview

A Phase 4 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started Feb 2020; status: completed.

02

Drugs

vortioxetine
03

Conditions

major depressive disorder (MDD)

Beyond the preview

Go deeper on NCT04288895.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04288895.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call